356 related articles for article (PubMed ID: 37473808)
21. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
Hao Y; Zhou X; Li Y; Li B; Cheng L
Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
[TBL] [Abstract][Full Text] [Related]
22. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
23. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
24. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
[TBL] [Abstract][Full Text] [Related]
25. Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRPα To Potentiate Antitumor Immunity.
Wang S; Jiao W; Yan B; Liu X; Tang Q; Zhang Y; Liang C; Wang X; Lyu Y; Fan H; Liu X
Nano Lett; 2024 Mar; 24(9):2894-2903. PubMed ID: 38407042
[TBL] [Abstract][Full Text] [Related]
26. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
[TBL] [Abstract][Full Text] [Related]
27. M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy.
Zhao W; Hu X; Li W; Li R; Chen J; Zhou L; Qiang S; Wu W; Shi S; Dong C
Small; 2021 Apr; 17(13):e2007051. PubMed ID: 33599061
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
30. Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
Stefanidis E; Semilietof A; Pujol J; Seijo B; Scholten K; Zoete V; Michielin O; Sandaltzopoulos R; Coukos G; Irving M
J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38828721
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.
Chen XJ; Guo CH; Wang ZC; Yang Y; Pan YH; Liang JY; Sun MG; Fan LS; Liang L; Wang W
Cell Commun Signal; 2024 Jan; 22(1):15. PubMed ID: 38183060
[TBL] [Abstract][Full Text] [Related]
32. Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer.
Chang R; Chu X; Zhang J; Fu R; Feng C; Jia D; Wang R; Yan H; Li G; Li J
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049910
[TBL] [Abstract][Full Text] [Related]
33. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
[TBL] [Abstract][Full Text] [Related]
35. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
36. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
37. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
38. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
Xiao A; Akilov OE
Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
[TBL] [Abstract][Full Text] [Related]
39. Lactate-Responsive Gene Editing to Synergistically Enhance Macrophage-Mediated Cancer Immunotherapy.
Li Y; Wei Y; Huang Y; Qin G; Zhao C; Ren J; Qu X
Small; 2023 Aug; 19(35):e2301519. PubMed ID: 37156740
[TBL] [Abstract][Full Text] [Related]
40. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.
Cheng L; Zhang X; Tang J; Lv Q; Liu J
Biomaterials; 2021 Aug; 275():120964. PubMed ID: 34147721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]